Sarepta Therapeutics (SRPT) announced AdCom to be held for SRP-9001
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Sarepta (SRPT) sinks 20% as surprise FDA AdComm for SRP-9001 adds risk
March 17, 2023 6:52 AM EDTShares of Sarepta Therapeutics (NASDAQ: SRPT) fell 20% in pre-open trading Friday after the company announced a surprise FDA AdComm for SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy. The news comes just a few weeks after management indicated that there would be no AdComm.
While the news adds a layer of risk, most analysts still expected FDA approval at the May 29th PDUFA date.
"FDAs decision to hold a public advisory committee meeting on the SRP 9001 BLA is a change from the communicated... More
